NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Tyra Biosciences Receives Buy Rating – Key 2026 Data Ahead

Tyra Biosciences’ dabogratinib shows promise: works well for bladder cancer & dwarfism with fewer side effects. Big 2026 trials ahead.

Tyra Biosciences Receives Buy Rating – Key 2026 Data Ahead
Credit: Tyra Biosciences
Already have an account? Sign in.
04/06/2026 · 7:00 AM
TYRA
/ Don’t stop at just one post.

Related↓

Tyra Biosciences Faces Investor Pressure After Pushing Back Key Trial Timelines
08/05/2026 · 1:19 PM

Tyra Biosciences Faces Investor Pressure After Pushing Back Key Trial Timelines

TYRA shares fell after Q2 results showed delayed BEACH301 and SURF302 data, a wider $45.6M loss, and potential dilution from a new $250M ATM.

/ Subscriber only
/ Read more

Feed↓

Crocs’ Ghost Office in Malta: The New Way U.S. Companies Dodge Taxes
08/05/2026 · 3:40 PM

Crocs’ Ghost Office in Malta: The New Way U.S. Companies Dodge Taxes

Crocs claims all global profits from a two-person Malta office, saving $218.6 million in 2023 taxes; shares slide after report.

/ Subscriber only
Tyra Biosciences Faces Investor Pressure After Pushing Back Key Trial Timelines
08/05/2026 · 1:19 PM

Tyra Biosciences Faces Investor Pressure After Pushing Back Key Trial Timelines

TYRA shares fell after Q2 results showed delayed BEACH301 and SURF302 data, a wider $45.6M loss, and potential dilution from a new $250M ATM.

/ Subscriber only
Starboard Value Takes Major Stake in Shake Shack as Q2 Sales Rise but Profits Slip
Featured/ 08/05/2026 · 12:36 PM

Starboard Value Takes Major Stake in Shake Shack as Q2 Sales Rise but Profits Slip

Shake Shack reports 17% revenue growth and 3.5% same-store sales, but profits slip as Starboard Value builds a major position.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe